Researchers track gene changes in myelofibrosis patients on gecacitinib
NCT ID NCT07342712
First seen Jan 18, 2026 · Last updated May 13, 2026 · Updated 13 times
Summary
This study follows about 40 people with intermediate- or high-risk myelofibrosis who have already been taking gecacitinib in earlier studies. Researchers will collect bone marrow and blood samples once a year to see if the disease grade or certain gene mutations change over time. No new treatments are given—this is an observational study to understand long-term effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310000, China
Conditions
Explore the condition pages connected to this study.